| Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer (NCT07698054) | Henan Cancer Hospital | 2026-08-01 |
| Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer (NCT07706933) | Henan Cancer Hospital | 2026-08-01 |
| AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer (NCT07757022) | Henan Cancer Hospital | 2026-07-30 |
| A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy (NCT07559786) | Henan Cancer Hospital | 2026-07-17 |
| Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma (NCT07459608) | Henan Cancer Hospital | 2026-07-10 |
| Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy (NCT07684950) | Henan Cancer Hospital | 2026-06-30 |
| Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer (NCT07702305) | Henan Cancer Hospital | 2026-06-23 |
| Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy (NCT07629817) | Henan Cancer Hospital | 2026-06-16 |
| A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors (NCT07618546) | Henan Cancer Hospital | 2026-05-25 |
| Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer (NCT07610629) | Henan Cancer Hospital | 2026-05-05 |
| A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron (NCT07442890) | Henan Cancer Hospital | 2026-04-30 |
| CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma (NCT07492407) | Henan Cancer Hospital | 2026-04-01 |
| Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma (NCT07472621) | Henan Cancer Hospital | 2026-03-10 |
| Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer (NCT07416253) | Henan Cancer Hospital | 2026-03-01 |
| Anlotinib in Cross-line Treatment of NSCLC and SCLC (NCT07400575) | Henan Cancer Hospital | 2026-02-01 |
| Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial (NCT07332221) | Henan Cancer Hospital | 2026-01-20 |
| A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer (NCT07540533) | Henan Cancer Hospital | 2026-01-20 |
| Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus (NCT07363512) | Henan Cancer Hospital | 2026-01-05 |
| Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology (NCT07203690) | Henan Cancer Hospital | 2025-12-01 |
| Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer (NCT07256964) | Henan Cancer Hospital | 2025-11-26 |
| Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma (NCT07233720) | Henan Cancer Hospital | 2025-11-18 |
| SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer (NCT07125950) | Henan Cancer Hospital | 2025-09-30 |
| QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer (NCT06967103) | Henan Cancer Hospital | 2025-09-08 |
| Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer (NCT07559097) | Henan Cancer Hospital | 2025-09-08 |
| Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. (NCT07136974) | Henan Cancer Hospital | 2025-09-01 |
| Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases (NCT07100600) | Henan Cancer Hospital | 2025-08-30 |
| A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC) (NCT07108816) | Henan Cancer Hospital | 2025-08-15 |
| Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 (NCT07264569) | Henan Cancer Hospital | 2025-06-25 |
| Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (NCT07057427) | Henan Cancer Hospital | 2025-06-24 |
| SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer (NCT06819319) | Henan Cancer Hospital | 2025-06-23 |
| Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors (NCT06955390) | Henan Cancer Hospital | 2025-05-01 |
| The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer (NCT06934733) | Henan Cancer Hospital | 2025-05-01 |
| SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC (NCT06927180) | Henan Cancer Hospital | 2025-04-16 |
| Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer (NCT06860529) | Henan Cancer Hospital | 2025-04-15 |
| A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis (NCT06945705) | Henan Cancer Hospital | 2025-04-02 |
| Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain (NCT06897917) | Henan Cancer Hospital | 2025-04-01 |
| Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (NCT06888531) | Henan Cancer Hospital | 2025-03-08 |
| A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients (NCT06788197) | Henan Cancer Hospital | 2025-03-01 |
| Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI (NCT06833775) | Henan Cancer Hospital | 2025-03-01 |
| Organoid-guided Personalized Treatment of Pleural Effusion (NCT06959173) | Henan Cancer Hospital | 2025-02-21 |
| Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC (NCT07244016) | Henan Cancer Hospital | 2025-02-20 |
| Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure (NCT06786208) | Henan Cancer Hospital | 2025-02-01 |
| Mechanistic Study on the Diagnosis of Esophageal Cancer Lymph Node Metastasis Using Spectral CT, Multimodal MRI, FAPI PET-CT, Pathology, and AI Evaluation System (NCT06818214) | Henan Cancer Hospital | 2025-02-01 |
| Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia (NCT06793228) | Henan Cancer Hospital | 2025-01-15 |
| Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN (NCT07187908) | Henan Cancer Hospital | 2025-01-01 |
| Application of LARS Ligament in Bone Prosthesis Replacement (NCT05616182) | Henan Cancer Hospital | 2024-12-30 |
| Application of Douyin in Perioperative Period of Malignant Tumor Patients (NCT05598229) | Henan Cancer Hospital | 2024-12-28 |
| Application of Antiosteoporosis Therapy in Osteolysis (NCT05617846) | Henan Cancer Hospital | 2024-12-28 |
| Application of Douyin in Patients With Bone and Soft Tissue Malignant Tumors During Perichemotherapy (NCT05598827) | Henan Cancer Hospital | 2024-12-28 |
| Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors (NCT05616195) | Henan Cancer Hospital | 2024-12-28 |
| Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis (NCT06643000) | Henan Cancer Hospital | 2024-12-20 |
| NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. (NCT06781281) | Henan Cancer Hospital | 2024-12-04 |
| Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (NCT06817525) | Henan Cancer Hospital | 2024-11-06 |
| Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study (NCT06685354) | Henan Cancer Hospital | 2024-11-01 |
| Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation (NCT07037537) | Henan Cancer Hospital | 2024-10-30 |
| Local Injection and Systemic Therapy in the Treatment of NSCLC. (NCT06618391) | Henan Cancer Hospital | 2024-10-08 |
| RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors (NCT06545201) | Henan Cancer Hospital | 2024-08-01 |
| Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) (NCT06454890) | Henan Cancer Hospital | 2024-08-01 |
| Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs (NCT06475443) | Henan Cancer Hospital | 2024-06-15 |
| L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma (NCT06478381) | Henan Cancer Hospital | 2024-06-01 |
| Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC (NCT06465238) | Henan Cancer Hospital | 2024-06-01 |
| This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT06427213) | Henan Cancer Hospital | 2024-05-20 |
| Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer (NCT06518135) | Henan Cancer Hospital | 2024-04-30 |
| Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer (NCT06394661) | Henan Cancer Hospital | 2024-04-28 |
| Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer (NCT06406660) | Henan Cancer Hospital | 2024-04-16 |
| Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer (NCT06406608) | Henan Cancer Hospital | 2024-04-16 |
| Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma (NCT06749730) | Henan Cancer Hospital | 2024-04-01 |
| RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors (NCT06546150) | Henan Cancer Hospital | 2024-03-01 |
| Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients (NCT06285149) | Henan Cancer Hospital | 2024-03-01 |
| An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer (NCT06436885) | Henan Cancer Hospital | 2024-02-28 |
| Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer (NCT06329973) | Henan Cancer Hospital | 2024-02-28 |
| A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer (NCT06267170) | Henan Cancer Hospital | 2024-02-25 |
| TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer (NCT06293014) | Henan Cancer Hospital | 2024-02-23 |
| Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer (NCT07334431) | Henan Cancer Hospital | 2024-02-22 |
| Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer (NCT06236997) | Henan Cancer Hospital | 2024-02-10 |
| Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression (NCT06227325) | Henan Cancer Hospital | 2024-02-01 |
| Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer (NCT06276868) | Henan Cancer Hospital | 2024-01-20 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) (NCT06231680) | Henan Cancer Hospital | 2024-01-19 |
| Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib (NCT06478927) | Henan Cancer Hospital | 2024-01-15 |
| Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial (NCT06176534) | Henan Cancer Hospital | 2024-01-01 |
| First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy (NCT06586697) | Henan Cancer Hospital | 2023-12-01 |
| The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) (NCT06160362) | Henan Cancer Hospital | 2023-10-31 |
| A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer (NCT06406673) | Henan Cancer Hospital | 2023-10-16 |
| A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG (NCT06774222) | Henan Cancer Hospital | 2023-09-12 |
| Go-CHOP as the Frontline Therapy for PTCL (NCT05963347) | Henan Cancer Hospital | 2023-08-03 |
| A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer (NCT05911958) | Henan Cancer Hospital | 2023-07-05 |
| RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies (NCT05923541) | Henan Cancer Hospital | 2023-06-26 |
| Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin (NCT05886140) | Henan Cancer Hospital | 2023-06-08 |
| Real World Study of Oxycodone Sustained-release Tablets for Patients With Moderate to Severe Cancer Pain (NCT05962294) | Henan Cancer Hospital | 2023-06-01 |
| Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma (NCT05900089) | Henan Cancer Hospital | 2023-05-30 |
| Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors (NCT05596344) | Henan Cancer Hospital | 2023-05-20 |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure (NCT06334757) | Henan Cancer Hospital | 2023-05-08 |
| Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC (NCT05918328) | Henan Cancer Hospital | 2023-05-03 |
| Lenvatinib for Advanced Bone and Soft Tissue Sarcoma (NCT05617859) | Henan Cancer Hospital | 2023-04-30 |
| To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients (NCT06605521) | Henan Cancer Hospital | 2023-04-04 |
| Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases (NCT05769010) | Henan Cancer Hospital | 2023-03-31 |
| Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma (NCT05718778) | Henan Cancer Hospital | 2023-03-20 |
| Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes (NCT05608785) | Henan Cancer Hospital | 2023-01-01 |
| PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma (NCT05466474) | Henan Cancer Hospital | 2022-12-30 |
| Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer (NCT05647330) | Henan Cancer Hospital | 2022-12-15 |